Changes in sleepiness and 24-h blood pressure following 4 months of CPAP treatment are not mediated by ICAM-1
| Autor: | Sandra B. Dunbar, Allan I. Pack, Samuel T. Kuna, Thorarinn Gislason, David Maislin, Bryndis Benediktsdottir, Raymond R. Townsend, Brendan T. Keenan, Victoria M. Pak |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Ambulatory blood pressure Neurology Sleepiness medicine.medical_treatment Blood Pressure Article 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Humans Continuous positive airway pressure Aged Sleep Apnea Obstructive Continuous Positive Airway Pressure business.industry Epworth Sleepiness Scale Psychomotor vigilance task Blood Pressure Monitoring Ambulatory Middle Aged medicine.disease Intercellular Adhesion Molecule-1 nervous system diseases respiratory tract diseases Obstructive sleep apnea Blood pressure Treatment Outcome 030228 respiratory system Otorhinolaryngology Cardiology Female Neurology (clinical) business Body mass index 030217 neurology & neurosurgery Follow-Up Studies |
| Zdroj: | Sleep Breath |
| Popis: | OBJECTIVE: Continuous positive airway pressure (CPAP) therapy reduces circulating intercellular adhesion molecule 1 (ICAM-1) in adults with obstructive sleep apnea (OSA). ICAM-1 levels may affect the daytime sleepiness and elevated blood pressure associated with OSA. We evaluated the association of changes frombaselineinICAM-1withchanges of objective and subjective measures of sleepiness, as well as 24-h ambulatory blood pressure monitoring (ABPM) measures, following 4 months of CPAP treatment. METHODS: The study sample included adults with newly diagnosed OSA. Plasma ICAM-1, 24-h ABPM, Epworth Sleepiness Scale (ESS), and psychomotor vigilance task (PVT) were obtained at baseline and following adequate CPAP treatment. The associations between changes in natural log ICAM-1 and changes in the number of lapses on PVT, ESS score, and 24-h mean arterial blood pressure (MAP) were assessed using multivariate regression models, controlling for a priori baseline covariates of age, sex, BMI, race, site, smoking status, physical activity, anti-hypertensive medications, AHI, and daily hours of CPAP use. RESULTS: Among 140 adults (83% men), mean (± SD) body mass index (BMI) was 31.5 ± 4.2 kg/m(2), and apnea-hyopnea index (AHI) was 36.8 ± 15.3 events/h. Sleepiness measures, although not ICAM-1 or ABPM measures, improved significantly following CPAP treatment. We observed no statistically significant associations between the change in ICAM-1 and changes in sleepiness, MAP, or other ABPM measures. CONCLUSION: Changes in ICAM-1 levels were not related to changes in sleepiness or ABPM following CPAP treatment of adults with OSA. Future work should explore whether or not other biomarkers may have a role inmediating these treatment outcomes in adults with OSA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|